AI Generated Image
AI-Designed Drug Might Slow Biological Aging
Newser • • general
Key Points:
- Insilico Medicine developed an AI-designed drug, rentosertib, which in a 12-week trial appeared to reduce biological age markers in patients, suggesting potential anti-aging effects.
- The trial involved 42 participants, with those taking rentosertib showing improvements on six different AI-powered aging clocks, while placebo or untreated groups did not exhibit similar changes.
- Originally intended to treat idiopathic pulmonary fibrosis (IPF), rentosertib also demonstrated increased lung capacity in IPF patients during earlier trial phases.
- Despite promising biomarker shifts, the reliability of aging clocks in predicting health outcomes remains debated among scientists, casting uncertainty on the drug’s anti-aging claims.
- Rentosertib will require extensive further testing and regulatory approval, and has yet to demonstrate anti-aging benefits in healthy individuals.
